Delta Lloyd NV boosted its stake in shares of Zimmer Biomet Holdings Inc. (NYSE:ZBH) by 25.2% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 14,642 shares of the company’s stock after buying an additional 2,947 shares during the period. Delta Lloyd NV’s holdings in Zimmer Biomet Holdings were worth $1,904,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently modified their holdings of the stock. IFP Advisors Inc increased its stake in shares of Zimmer Biomet Holdings by 0.5% in the second quarter. IFP Advisors Inc now owns 1,507 shares of the company’s stock valued at $181,000 after buying an additional 8 shares in the last quarter. Cypress Wealth Advisors LLC increased its stake in shares of Zimmer Biomet Holdings by 0.4% in the second quarter. Cypress Wealth Advisors LLC now owns 3,081 shares of the company’s stock valued at $371,000 after buying an additional 11 shares in the last quarter. Advisory Services Network LLC increased its stake in shares of Zimmer Biomet Holdings by 0.6% in the second quarter. Advisory Services Network LLC now owns 2,496 shares of the company’s stock valued at $301,000 after buying an additional 15 shares in the last quarter. Capital One National Association increased its stake in shares of Zimmer Biomet Holdings by 0.3% in the third quarter. Capital One National Association now owns 5,670 shares of the company’s stock valued at $738,000 after buying an additional 15 shares in the last quarter. Finally, Pointe Capital Management LLC increased its stake in shares of Zimmer Biomet Holdings by 0.8% in the third quarter. Pointe Capital Management LLC now owns 2,626 shares of the company’s stock valued at $341,000 after buying an additional 21 shares in the last quarter. Institutional investors own 85.05% of the company’s stock.

Institutional Ownership by Quarter for Zimmer Biomet Holdings (NYSE:ZBH)

Zimmer Biomet Holdings Inc. (NYSE:ZBH) traded up 1.39% on Tuesday, hitting $103.40. 2,183,053 shares of the stock were exchanged. Zimmer Biomet Holdings Inc. has a 12 month low of $88.27 and a 12 month high of $133.21. The firm has a market cap of $20.71 billion, a P/E ratio of 57.89 and a beta of 1.28. The company has a 50-day moving average of $112.33 and a 200 day moving average of $121.63.

Zimmer Biomet Holdings (NYSE:ZBH) last issued its quarterly earnings data on Monday, October 31st. The company reported $1.79 earnings per share for the quarter, meeting the Zacks’ consensus estimate of $1.79. The company had revenue of $1.83 billion for the quarter, compared to the consensus estimate of $950.20 million. Zimmer Biomet Holdings had a net margin of 3.46% and a return on equity of 16.48%. The firm’s revenue for the quarter was up 4.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.64 earnings per share. Equities research analysts expect that Zimmer Biomet Holdings Inc. will post $7.92 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Delta Lloyd NV Increases Position in Zimmer Biomet Holdings Inc. (ZBH)” was first published by Financial Market News and is the sole property of of Financial Market News. If you are reading this piece on another domain, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The correct version of this piece can be read at http://www.financial-market-news.com/delta-lloyd-nv-increases-position-in-zimmer-biomet-holdings-inc-zbh/1209317/.

A number of research firms have issued reports on ZBH. Citigroup Inc. upgraded Zimmer Biomet Holdings from a “sell” rating to a “neutral” rating in a research note on Tuesday. Needham & Company LLC upgraded Zimmer Biomet Holdings from a “buy” rating to a “strong-buy” rating and cut their price target for the company from $150.00 to $148.00 in a research note on Tuesday, November 1st. SunTrust Banks Inc. began coverage on Zimmer Biomet Holdings in a research note on Thursday, August 11th. They set a “buy” rating and a $155.00 price target for the company. Leerink Swann reiterated an “outperform” rating and set a $136.00 price target (down previously from $150.00) on shares of Zimmer Biomet Holdings in a research note on Tuesday, November 1st. Finally, Jefferies Group reiterated a “buy” rating and set a $150.00 price target on shares of Zimmer Biomet Holdings in a research note on Monday, August 8th. Four investment analysts have rated the stock with a hold rating, twenty have issued a buy rating and one has assigned a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $131.15.

In related news, insider Daniel E. Williamson sold 2,716 shares of the stock in a transaction that occurred on Thursday, September 8th. The shares were sold at an average price of $129.96, for a total transaction of $352,971.36. Following the transaction, the insider now owns 2,000 shares in the company, valued at $259,920. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 1.22% of the company’s stock.

Zimmer Biomet Holdings Company Profile

Zimmer Biomet Holdings, Inc, formerly Zimmer Holdings, Inc, is engaged designing, manufacturing and marketing orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

5 Day Chart for NYSE:ZBH

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings Inc. (NYSE:ZBH).

Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.